J. Lynch Brian's Insider Trades & SAST Disclosures
J. Lynch Brian's most recent trade in Carters Inc was a trade of 1,893 Common Stock done at an average price of $80.5 . Disclosure was reported to the exchange on Feb. 27, 2024.
Add Superstar Alert
Share
Note
This is a custom search result for pattern J. Lynch Brian.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
|
Carters Inc
|
Brian Lynch J. | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 80.55 per share. | 27 Feb 2024 | 1,893 | 86,641 (0%) | 0% | 80.5 | 152,481 | Common Stock |
|
Carters Inc
|
J. Lynch Brian | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.40 per share. | 16 Feb 2024 | 1,231 | 88,534 (0%) | 0% | 81.4 | 100,203 | Common Stock |
|
Carters Inc
|
Lynch J. Brian | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.81 per share. | 12 Feb 2024 | 661 | 89,765 (0%) | 0% | 81.8 | 54,076 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 81.21 per share. | 10 Feb 2024 | 7,474 | 90,426 (0%) | 0% | 81.2 | 606,964 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Lynch Brian Joseph | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 5,483 | 5,483 | - | - | Stock Option (Right to Buy) | |
|
Madrigal Pharmaceuticals Inc
|
Lynch Joseph Brian | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 3,639 | 17,691 (0%) | 0% | 0 | Common Stock | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2024 | 3,639 | 3,639 | - | - | Market Stock Unit | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Payment of exercise price or tax liability using portion of securities received from the company at price $ 243.92 per share. | 16 Jan 2024 | 949 | 14,052 (0%) | 0% | 243.9 | 231,480 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Lynch Joseph Brian | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 221.38 per share. | 04 Dec 2023 | 1,000 | 15,001 (0%) | 0% | 221.4 | 221,380 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Joseph Brian Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 1,000 | 44,000 | - | - | Stock Option (Right to Buy) | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 1,000 | 43,000 | - | - | Stock Option (Right to Buy) | |
|
Madrigal Pharmaceuticals Inc
|
Joseph Lynch Brian | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 04 Dec 2023 | 1,000 | 16,001 (0%) | 0% | 87.1 | 87,090 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Lynch Brian Joseph | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 87.09 per share. | 04 Dec 2023 | 1,000 | 16,801 (0%) | 0% | 87.1 | 87,090 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Lynch Brian Joseph | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 227.33 per share. | 04 Dec 2023 | 1,000 | 15,001 (0%) | 0% | 227.3 | 227,330 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Joseph Lynch Brian | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 73.75 per share. | 04 Dec 2023 | 800 | 15,801 (0%) | 0% | 73.8 | 59,000 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 215.73 per share. | 04 Dec 2023 | 800 | 16,001 (0%) | 0% | 215.7 | 172,584 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Lynch Brian Joseph | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Dec 2023 | 800 | 20,200 | - | - | Stock Option (Right to Buy) | |
|
Carters Inc
|
Brian J. Lynch | President & COO | Sale of securities on an exchange or to another person at price $ 70.11 per share. | 02 Nov 2023 | 12,000 | 97,900 (0%) | 0% | 70.1 | 841,320 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2023 | 4,100 | 3,400 | - | - | Employee Stock Option (Right to Purchase) | |
|
Carters Inc
|
Brian J. Lynch | President & COO | Sale of securities on an exchange or to another person at price $ 68.78 per share. | 02 Nov 2023 | 4,100 | 109,900 (0%) | 0% | 68.8 | 281,998 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.49 per share. | 02 Nov 2023 | 4,100 | 114,000 (0%) | 0% | 68.5 | 280,809 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Nov 2023 | 3,400 | 0 | - | - | Employee Stock Option (Right to Purchase) | |
|
Carters Inc
|
Brian J. Lynch | President & COO | Sale of securities on an exchange or to another person at price $ 69.29 per share. | 02 Nov 2023 | 3,400 | 109,900 (0%) | 0% | 69.3 | 235,586 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 68.49 per share. | 02 Nov 2023 | 3,400 | 113,300 (0%) | 0% | 68.5 | 232,866 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 16,880 | 109,900 (0%) | 0% | 0 | Common Stock | |
|
Carters Inc
|
Brian J. Lynch | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 16,880 | 93,020 (0%) | 0% | 0 | Common Stock | |
|
Carters Inc
|
Brian J. Lynch | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.72 per share. | 16 Feb 2023 | 1,238 | 76,140 (0%) | 0% | 77.7 | 96,217 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 78.86 per share. | 13 Feb 2023 | 699 | 77,378 (0%) | 0% | 78.9 | 55,123 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.40 per share. | 10 Feb 2023 | 1,534 | 78,742 (0%) | 0% | 77.4 | 118,732 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President & COO Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 77.40 per share. | 10 Feb 2023 | 665 | 78,077 (0%) | 0% | 77.4 | 51,471 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jan 2023 | 15,001 | 15,001 (0%) | 0% | 0 | Common Stock | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.79 per share. | 03 Jan 2023 | 13,000 | 13,000 (0%) | 0% | 91.8 | 1,193,270 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2023 | 13,000 | 12,000 | - | - | Stock Option (Right to Buy) | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 281.97 per share. | 03 Jan 2023 | 2,656 | 7,544 (0%) | 0% | 282.0 | 748,912 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 282.97 per share. | 03 Jan 2023 | 2,628 | 4,916 (0%) | 0% | 283.0 | 743,645 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 285.74 per share. | 03 Jan 2023 | 2,038 | 500 (0%) | 0% | 285.7 | 582,338 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 280.66 per share. | 03 Jan 2023 | 1,800 | 10,200 (0%) | 0% | 280.7 | 505,188 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 283.85 per share. | 03 Jan 2023 | 1,549 | 3,367 (0%) | 0% | 283.9 | 439,684 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 285.15 per share. | 03 Jan 2023 | 829 | 2,538 (0%) | 0% | 285.1 | 236,389 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 277.91 per share. | 03 Jan 2023 | 600 | 12,400 (0%) | 0% | 277.9 | 166,746 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 279.10 per share. | 03 Jan 2023 | 400 | 12,000 (0%) | 0% | 279.1 | 111,640 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 286.62 per share. | 03 Jan 2023 | 400 | 100 (0%) | 0% | 286.6 | 114,648 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 287.86 per share. | 03 Jan 2023 | 100 | 0 (0%) | 0% | 287.9 | 28,786 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Dec 2022 | 7,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Exercise or conversion of derivative security received from the company (such as an option) at price $ 91.79 per share. | 23 Dec 2022 | 7,000 | 7,000 (0%) | 0% | 91.8 | 642,530 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 272.74 per share. | 23 Dec 2022 | 1,500 | 3,200 (0%) | 0% | 272.7 | 409,110 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 279.46 per share. | 23 Dec 2022 | 1,100 | 600 (0%) | 0% | 279.5 | 307,406 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 271.27 per share. | 23 Dec 2022 | 800 | 4,700 (0%) | 0% | 271.3 | 217,016 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 270.25 per share. | 23 Dec 2022 | 700 | 5,500 (0%) | 0% | 270.3 | 189,175 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 273.48 per share. | 23 Dec 2022 | 539 | 2,661 (0%) | 0% | 273.5 | 147,406 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 267.88 per share. | 23 Dec 2022 | 500 | 6,500 (0%) | 0% | 267.9 | 133,940 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 274.70 per share. | 23 Dec 2022 | 400 | 2,261 (0%) | 0% | 274.7 | 109,880 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 277.77 per share. | 23 Dec 2022 | 361 | 1,700 (0%) | 0% | 277.8 | 100,275 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 268.99 per share. | 23 Dec 2022 | 300 | 6,200 (0%) | 0% | 269.0 | 80,697 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 283.61 per share. | 23 Dec 2022 | 200 | 0 (0%) | 0% | 283.6 | 56,722 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 281.79 per share. | 23 Dec 2022 | 200 | 200 (0%) | 0% | 281.8 | 56,358 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 280.41 per share. | 23 Dec 2022 | 200 | 400 (0%) | 0% | 280.4 | 56,082 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 276.40 per share. | 23 Dec 2022 | 100 | 2,061 (0%) | 0% | 276.4 | 27,640 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Sale of securities on an exchange or to another person at price $ 275.24 per share. | 23 Dec 2022 | 100 | 2,161 (0%) | 0% | 275.2 | 27,524 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Sale of securities on an exchange or to another person at price $ 72.59 per share. | 02 Dec 2022 | 4,500 | 80,276 (0%) | 0% | 72.6 | 326,655 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Dec 2022 | 4,500 | 0 | - | - | Employee Stock Option (Right to Purchase) | |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 59.27 per share. | 02 Dec 2022 | 4,500 | 84,776 (0%) | 0% | 59.3 | 266,715 | Common Stock |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Aug 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.91 per share. | 25 Feb 2022 | 2,095 | 80,276 (0%) | 0% | 96.9 | 203,026 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Sale or transfer of securities back to the company at price $ 0.00 per share. | 25 Feb 2022 | 1,548 | 82,371 (0%) | 0% | 0 | Common Stock | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Councel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2022 | 45,000 | 45,000 | - | - | Stock Option (Right to Buy) | |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.48 per share. | 21 Feb 2022 | 258 | 83,919 (0%) | 0% | 88.5 | 22,828 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 10,976 | 84,177 (0%) | 0% | 0 | Common Stock | |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2022 | 10,976 | 73,201 (0%) | 0% | 0 | Common Stock | |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.49 per share. | 12 Feb 2022 | 699 | 62,225 (0%) | 0% | 92.5 | 64,651 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.49 per share. | 12 Feb 2022 | 665 | 62,924 (0%) | 0% | 92.5 | 61,506 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 94.27 per share. | 10 Feb 2022 | 1,521 | 63,589 (0%) | 0% | 94.3 | 143,385 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Sale of securities on an exchange or to another person at price $ 101.89 per share. | 03 Nov 2021 | 15,900 | 65,110 (0%) | 0% | 101.9 | 1,620,051 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Sale or transfer of securities back to the company at price $ 0.00 per share. | 26 Feb 2021 | 10,468 | 81,010 (0%) | 0% | 0 | Common Stock | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | SVP and General Councel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2021 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.54 per share. | 21 Feb 2021 | 258 | 91,478 (0%) | 0% | 92.5 | 23,875 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.36 per share. | 12 Feb 2021 | 699 | 92,109 (0%) | 0% | 96.4 | 67,356 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.36 per share. | 12 Feb 2021 | 672 | 92,808 (0%) | 0% | 96.4 | 64,754 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 96.36 per share. | 12 Feb 2021 | 373 | 91,736 (0%) | 0% | 96.4 | 35,942 | Common Stock |
|
Carters Inc
|
Brian J. Lynch | President, Carters, Inc. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2021 | 26,520 | 93,480 (0%) | 0% | 0 | Common Stock | |
|
Madrigal Pharmaceuticals Inc
|
Brian Joseph Lynch | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Aug 2020 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges